Emerging infectious diseases, the persistent potential for destabilising pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarise current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.

新兴的传染病，破坏大流行病的持续潜力，仍然是导致过度发病和死亡的全球威胁。目前由2019年新型冠状病毒（COVID-19）引起的肺炎暴发说明了缺乏有效的治疗药物存在的困难。准确，快速的诊断工具对于传染病的早期识别和治疗必不可少，可以及时实施感染控制，改善临床护理和其他公共卫生措施以阻止疾病的传播。CRISPR-Cas技术可快速，准确地加快传染病诊断程序的开发。在这篇综述中，我们总结了快速CRISPR / Cas9，CRISPR-Cas12和CRISPR-Cas13等多种CRISPR-Cas系统的最新进展，